Ching-Hsien Chen, Ph.D.

Ching-Hsien Chen, Ph.D.

Specialties

Molecular Cancer Biology

Peptide-based Therapeutics

Functional Proteomics

Department

Internal Medicine

Title

  • Assistant Adjunct Professor
To see if Ching-Hsien Chen is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).

Clinical Interests

Dr. Chen has had a passion for understanding and improving the treatment of neoplastic diseases. She has established close collaborations with physician scientists to discover novel useful biomarkers that stratify clinicopathological subtypes of solid tumors. These biomarkers will be used to predict treatment outcomes of cancer patients undergoing clinical trials with combined inhibitors specifically targeting aberrant oncogenic signaling.

Research/Academic Interests

Dr. Chen’s research strives to elucidate the molecular mechanisms underlying human diseases and thereby identify useful biomarkers and druggable targets in a broad range of malignancies. In the last five years, her studies have revealed multiple oncogenic complexes and have also developed the peptide-based therapeutics to mitigate cancer metastasis and drug resistance.

Currently, the research foci of Dr. Chen’s laboratory are 1) to discover potential therapeutic targets in renal cell carcinoma and polycystic kidney disease using integrated -omics data, genetic manipulations and pharmacological approaches; 2) to develop clinically viable methods of ex-vivo expansion and activation of tumor propagating cells. In addition, Dr. Chen is actively engaging in the feasibility of PIP2 retention strategies on controlling cancer progression and increasing the efficacy of chemo- or immunotherapy.

Division

Nephrology

Center/Program Affiliation

UC Davis Comprehensive Cancer Center

Education

M.S., China Medical University, Taichung, Taiwan 2004

Ph.D., National Chung Hsing University, Taichung, Taiwan 2011

B.S., China Medical University, Taichung, Taiwan 2000

Fellowships

Internal Medicine/Cancer, National Taiwan University, Taipei, Taiwan 2011-2012

Internal Medicine/Cancer, UC Davis Medical Center, Sacramento CA 2012-2016

Professional Memberships

American Association for Cancer Research

American Society of Clinical Oncology

American Society of Nephrology

American Thoracic Society

Honors and Awards

2016 ASN Kidney Week Travel Award, The American Society of Nephrology, USA, 2016

2015 Award for Excellence in Postdoctoral Research (Nominee), UC Davis, CA, 2015

TRDRP Postdoctoral Fellowship Award, 2014

2014 The Department of Internal Medicine Trainee Research Award, UC Davis, CA, 2014

Phil Thai Memorial Award, 5th Annual Lung Research Symposium, UC Davis, CA, 2014

2013 The Department of Internal Medicine Trainee Research Award, UC Davis, CA, 2013

Select Recent Publications

Chen CH, Chang WH, Su KY, Ku WH, Chang GC, Hong QS, Hsiao YJ, Chen HC, Chen HY, Wu R, Yang PC, Chen JJW, Yu SL. HLJ1 is an endogenous Src inhibitor suppressing cancer progression through dual mechanisms. Oncogene. 2016.

Chen CH, Cheng CT, Yuan Y, Zhai J, Arif M, Fong LW, Wu R and Ann DK. Elevated MARCKS phosphorylation contributes to unresponsiveness of breast cancer to paclitaxel treatment. Oncotarget. 2015 20;6(17):15194-208.

Chen CH, Statt S, Chiu CL, Thai P, Arif M, Adler KB, and Wu R. Targeting myristoylated alanine-rich C kinase substrate phosphorylation site domain in lung cancer. Mechanisms and therapeutic implications. Am. J. Respir. Crit. Care Medicine. 2014; 190(10):1127-38.

Chen CH, Chiu CL, Adler KB and Wu R. A novel predictor of cancer malignancy: Up-regulation of MARCKS phosphorylation in lung cancer. Am. J. Respir. Crit. Care Medicine. 2014; 189(8):1002-4.

Chen CH, Thai P, Yoneda K, Adler KB, Yang PC and Wu R. A peptide that inhibits function of Myristoylated Alanine - Rich C Kinase Substrate (MARCKS) reduces lung cancer metastasis. Oncogene. 2014;10; 33(28):3696-706.

Chen CH, Yang MF, Liao JW, Yu SL, Chen JJW. A Novel Function of YWHAZ/β-catenin Axis in Promoting Epithelial-Mesenchymal Transition and Lung Cancer Metastasis. Mol Cancer Res. 2012; 10(10):1319-31.

Chen CH, Lin H, Chuang SM, Lin SY, Chen JJW. Acidic stress facilitates tyrosine phosphorylation of HLJ1 to associate with actin cytoskeleton in lung cancer cells. Exp Cell Res. 2010;316:2910-21.

To view a detailed list of  Dr. Chen's publications, please click here.